MS
RPRX icon

Murray Stahl’s Royalty Pharma RPRX Stock Holding History

Murray Stahl’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Buy
344,861
+4,078
+1% +$212K 0.22% 39
2026
Q1 		$16.3M Sell
340,783
-12,578
-4% -$551K 0.18% 42
2025
Q4 		$13.7M Sell
353,361
-1,324
-0.4% -$50.5K 0.18% 46
2025
Q3 		$12.5M Buy
354,685
+1,214
+0.3% +$43.9K 0.15% 49
2025
Q2 		$12.7M Buy
353,471
+23,901
+7% +$792K 0.15% 50
2025
Q1 		$10.3M Buy
329,570
+10,394
+3% +$329K 0.12% 54
2024
Q4 		$8.14M Buy
319,176
+90,380
+40% +$2.4M 0.1% 57
2024
Q3 		$6.47M Buy
228,796
+12
+0% +$332 0.1% 63
2024
Q2 		$6.03M Buy
228,784
+28,496
+14% +$790K 0.11% 62
2024
Q1 		$6.08M Sell
200,288
-16,402
-8% -$484K 0.12% 57
2023
Q4 		$6.09M Sell
216,690
-70,565
-25% -$1.94M 0.13% 56
2023
Q3 		$7.8M Sell
287,255
-46,414
-14% -$1.38M 0.15% 53
2023
Q2 		$10.3M Sell
333,669
-39,451
-11% -$1.34M 0.22% 52
2023
Q1 		$13.4M Sell
373,120
-26,760
-7% -$992K 0.26% 44
2022
Q4 		$15.8M Sell
399,880
-8,666
-2% -$362K 0.26% 40
2022
Q3 		$16.4M Sell
408,546
-45,010
-10% -$1.92M 0.33% 37
2022
Q2 		$19.1M Buy
453,556
+62,638
+16% +$2.57M 0.4% 38
2022
Q1 		$15.2M Buy
390,918
+108,381
+38% +$4.26M 0.31% 46
2021
Q4 		$11.3M Buy
282,537
+42,209
+18% +$1.64M 0.25% 53
2021
Q3 		$8.69M Buy
240,328
+27,071
+13% +$1.05M 0.2% 54
2021
Q2 		$8.74M Buy
213,257
+163,492
+329% +$6.95M 0.18% 57
2021
Q1 		$2.17M Buy
+49,765
New +$2.36M 0.05% 112

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Murray Stahl's RPRX Position: Q2 2026 in Review

Murray Stahl increased its Royalty Pharma (RPRX) stake by 1.2% in Q2 2026, buying an estimated $212K and bringing the position to 344,861 shares worth $19.3M. The position accounts for 0.22% of the portfolio, ranked #39.

Murray Stahl first reported a position in RPRX in Q1 2021 and has held it in 22 quarters since. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Murray Stahl held 344,861 shares of Royalty Pharma worth $19.3M as of Q2 2026.
  • Murray Stahl bought 4,078 Royalty Pharma shares in Q2 2026, an estimated $212K.
  • Royalty Pharma made up 0.22% of Murray Stahl's portfolio in Q2 2026, its #39 holding.
  • Murray Stahl first reported a position in Royalty Pharma in Q1 2021 and has held it in 22 quarters since.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.